P2RY1 and stroke disorder: In PEGASUS-TIMI 54, treatment with ticagrelor 60 mg b.i.d. in patients more recent to their MI or ADP receptor blocker discontinuation, as recommended in the EU label, reduced the risk of CV death, MI, or stroke by 20%, CV death by 29%, and all-cause mortality by 20%.